SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Lin C, Kwong AD, Perni RB. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect Disord Drug Targets 2006; 6: 316.
  • 2
    McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, McNair L, Alam J, PROVE1 Study Team. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 182738. [erratum: N Engl J Med 2009; 361: 1516.].
  • 3
    Hézode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, Bronowicki JP, Bourlière M, Gharakhanian S, Bengtsson L, McNair L, George S, Kieffer T, Kwong A, Kauffman RS, Alam J, Pawlotsky JM, Zeuzem S, PROVE2 Study Team. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 183950.
  • 4
    McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, Heathcote EJ, Zeuzem S, Reesink HW, Garg J, Bsharat M, George S, Kauffman RS, Adda N, Di Bisceglie AM, PROVE3 Study Team. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 1292303. [erratum: N Engl J Med 2010; 362: 1647.].
  • 5
    Jacobson IM, McHutchison JG, Dusheiko GM, Di Bisceglie AM, Reddy KR, Bzowej NH, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S, ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 240516.
  • 6
    Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M, REALIZE Study Team. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 241728.
  • 7
    Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, Fried MW, Adler M, Reesink HW, Martin M, Sankoh AJ, Adda N, Kauffman RS, George S, Wright CI, Poordad, ILLUMINATE Study Team. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 101424. [Erratum: N Engl J Med 2011; 365: 1551].
  • 8
    INCIVEK [US prescribing information]. Cambridge, MA: Vertex Pharmaceuticals Incorporated; 2012. Available at http://pi.vrtx.com/files/uspi_telaprevir.pdf (last accessed 29 June 2012).
  • 9
    INCIVEK [Canada product monograph]. Laval, Quebec, Canada: Vertex Pharmaceuticals Incorporated; 2011. Available at http://pi.vrtx.com/files/canadapm_telaprevir_en.pdf (last accessed 29 June 2012).
  • 10
    INCIVO [EU summary of product characteristics]. Beerse, Belgium: Janssen Cilag NV; 2012. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002313/WC500115529.pdf (last accessed 29 June 2012).
  • 11
    TELAVIC [package insert]. Osaka, Japan: Mitsubishi Tanabe Pharma; 2011.
  • 12
    US Department of Health and Human Services. Guidance for industry: bioanalytical assay validation. 2001; Available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf (last accessed 29 June 2012).
  • 13
    Garg V, van Heeswijk R, Yang Y, Kauffman R, Smith F, Adda N. The pharmacokinetic interaction between an oral contraceptive containing ethinyl estradiol and norethindrone and the HCV protease inhibitor telaprevir. J Clin Pharmacol 2012; e-pub ahead of print, DOI: 10.1177/0091270011419855.
  • 14
    U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for Industry. Drug Interaction Studies – Study Design, Data Analysis, and Implications for Dosing and Labeling. September 2006.
  • 15
    Daneshmend TK, Warnock DW, Ene MD, Johnson EM, Potten MR, Richardson MD, Williamson PJ. Influence of food on the pharmacokinetics of ketoconazole. Antimicrob Agents Chemother 1984; 25: 13.
  • 16
    Niemi M Backman JT, Fromm MF, Neuvonen PJ, Kivistö KT. Pharmacokinetic interaction with rifampin: clinical relevance. Clin Pharmacokinet 2003; 42: 81950.
  • 17
    Rifampin Capsules [US prescribing information]. Marietta, Georgia: VersaPharm Incorporated; 2003. Available at http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=26a2dbca-5090-4f6c-99ed-e11a70bb5af0 (last accessed 29 June 2012).
  • 18
    Stoch SA, Friedman E, Maes A, Yee K, Xu Y, Larson P, Fitzgerald M, Chodakewitz J, Wagner JA. Effect of different durations of ketoconazole dosing on the single-dose pharmacokinetics of midazolam: Shortening the paradigm. J Clin Pharmacol 2009; 49: 398406.
  • 19
    Garg V, Chandorkar G, Farmer F, Smith F, Alves K, van Heeswijk RPG. The effect of telaprevir on the pharmacokinetics of midazolam and digoxin. J Clin Pharmacol 2012; e-pub ahead of print, DOI: 10.1177/0091270011419850.
  • 20
    REYATAZ. [US prescribing information]. 2011. Princeton, NJ: Bristol-Myers Squibb. Available at http://packageinserts.bms.com/pi/pi_reyataz.pdf (last accessed 29 June 2012).
  • 21
    KALETRA. [US prescribing information]. 2011. North Chicago, IL: Abbot Laboratories. Available at http://www.rxabbott.com/pdf/kaletratabpi.pdf (last accessed 29 June 2012).
  • 22
    Garg V, Luo X, McNair L, van Heeswijk R, Kauffman R. Low-dose ritonavir and the pharmacokinetics of the investigational HCV protease inhibitor telaprevir in healthy volunteers. Poster presented at: 18th Conference on Retroviruses and Opportunistic Infections; February 2011; Boston, MA. Abstract 629. Available at http://www.retroconference.org/2011/Abstracts/40192.htm (last accessed 29 June 2012).
  • 23
    NORVIR [US prescribing information]. 2012. North Chicago, IL: Abbot Laboratories. Available at http://www.rxabbott.com/pdf/norpi2a.pdf (last accessed 29 June 2012).
  • 24
    Venkatesan K. Pharmacokinetic drug interactions with rifampicin. Clin Pharmacokinet 1992; 22: 4765.
  • 25
    van Heeswijk R, Vandevoorde A, Boogaerts G, Vangeneugden T, de Paepe E, Polo R, van Solingen-Ristea R, de Backer K, Garg V, Beumont M. Pharmacokinetic interactions between antiretroviral agents and the investigational HCV protease inhibitor telaprevir in healthy volunteers. Oral presentation at: 18th Conference on Retroviruses and Opportunistic Infections; February 2011; Boston, MA. Abstract 119.
  • 26
    Sulkowski M, Dieterich D, Sherman K, Rockstroh JK, Adda N, Mahnke L, Garg V, Charakhanian S, McCallister S, Soriano V. Interim analysis of a phase 2a double-blind study of telaprevir in combination with pegylated interferon-α2a and ribavirin in HIV/HCV co-infected patients. Oral presentation at: 18th Conference on Retroviruses and Opportunistic Infections; February 2011; Boston, MA. Abstract 146LB. Available at http://www.retroconference.org/2011/Abstracts/42467.htm (last accessed 29 June 2012).
  • 27
    SUSTIVA [US prescribing information]. 2011. Princeton, New Jersey: Bristo-Myers Squibb. Available at http://packageinserts.bms.com/pi/pi_sustiva.pdf (last accessed 29 June 2012).
  • 28
    Skeie L, Maeland A. Can efavirenz be taken in the morning? Scan J Infect Dis 2006; 38: 108991.